{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:23:02Z","timestamp":1791156182683,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1038\/sj.bjc.6604269","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T14:57:54Z","timestamp":1204642674000},"page":"923-930","source":"Crossref","is-referenced-by-count":110,"title":["Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs"],"prefix":"10.1038","volume":"98","author":[{"given":"R","family":"Bianco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Gelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Marciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,4]]},"reference":[{"key":"BF6604269_CR1","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","volume":"13","author":"RT Abraham","year":"2007","unstructured":"Abraham RT, Gibbons JJ (2007) The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13: 3109\u20133114","journal-title":"Clin Cancer Res"},{"key":"BF6604269_CR2","doi-asserted-by":"publisher","first-page":"4446s","DOI":"10.1158\/1078-0432.CCR-06-0623","volume":"12","author":"AA Adjei","year":"2006","unstructured":"Adjei AA (2006) Novel combinations based on epidermal growth factor receptor inhibition. Clin Cancer Res 12: 4446s\u20134450s","journal-title":"Clin Cancer Res"},{"key":"BF6604269_CR3","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445\u20132459","journal-title":"J Clin Oncol"},{"key":"BF6604269_CR4","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1200\/JCO.2006.05.8073","volume":"24","author":"A Bezjak","year":"2006","unstructured":"Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24: 3831\u20133837","journal-title":"J Clin Oncol"},{"key":"BF6604269_CR5","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1038\/sj.onc.1206388","volume":"22","author":"R Bianco","year":"2003","unstructured":"Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani N, Dennis PA, Mills GB, Arteaga CL (2003) Loss of PTEN\/MMAC1\/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812\u20132822","journal-title":"Oncogene"},{"key":"BF6604269_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1677\/erc.1.00999","volume":"12","author":"R Bianco","year":"2005","unstructured":"Bianco R, Troiani T, Tortora G, Ciardiello F (2005) Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer 12: 159\u2013171","journal-title":"Endocr Relat Cancer"},{"key":"BF6604269_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335\u2013348","journal-title":"Nat Rev Cancer"},{"key":"BF6604269_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","volume":"64","author":"A Boulay","year":"2004","unstructured":"Boulay A, Zumstein-Mecke S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O\u2019Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252\u2013261","journal-title":"Cancer Res"},{"key":"BF6604269_CR9","first-page":"200","volume":"62","author":"A Chakravarti","year":"2002","unstructured":"Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200\u2013207","journal-title":"Cancer Res"},{"key":"BF6604269_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/1078-0432.CCR-1100-03","volume":"10","author":"F Ciardiello","year":"2004","unstructured":"Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784\u2013793","journal-title":"Clin Cancer Res"},{"key":"BF6604269_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","volume":"7","author":"A Citri","year":"2006","unstructured":"Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505\u2013516","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BF6604269_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337\u2013345","journal-title":"N Engl J Med"},{"key":"BF6604269_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1212\/01.wnl.0000223844.77636.29","volume":"67","author":"L Doherty","year":"2006","unstructured":"Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67: 156\u2013158","journal-title":"Neurology"},{"key":"BF6604269_CR14","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","volume":"25","author":"M Fouladi","year":"2007","unstructured":"Fouladi M, Laningham F, Wu J, O\u2019Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25: 4806\u20134812","journal-title":"J Clin Oncol"},{"key":"BF6604269_CR15","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/sj.bjc.6602646","volume":"92","author":"RM Gemmill","year":"2005","unstructured":"Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA (2005) Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer 92: 2266\u20132277","journal-title":"Br J Cancer"},{"key":"BF6604269_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.101.4.1","volume":"4","author":"RK Goudar","year":"2005","unstructured":"Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang X, Bigner DD, Friedman HS, Rich JN (2005) Combination therapy of inhibitors of epidermal growth factor receptor\/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4: 101\u2013112","journal-title":"Mol Cancer Ther"},{"key":"BF6604269_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M, Von Breitenbuch P, Steinbauer M, Koeh G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128\u2013135","journal-title":"Nat Med"},{"key":"BF6604269_CR18","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2004-09-3540","volume":"105","author":"M Guba","year":"2005","unstructured":"Guba M, Yezhelyev M, Eichorn ME, Schmid G, Ischenko I, Papyan A, Graeb C, Seeliger H, Geissler EK, Jauch KW, Bruns CJ (2005) Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 105: 4463\u20134469","journal-title":"Blood"},{"key":"BF6604269_CR19","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","volume":"27","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 27: 6680\u20136686","journal-title":"Oncogene"},{"key":"BF6604269_CR20","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271\u20132281","journal-title":"N Engl J Med"},{"key":"BF6604269_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341\u2013354","journal-title":"Nat Rev Cancer"},{"key":"BF6604269_CR22","first-page":"2316","volume":"9","author":"ML Janmaat","year":"2003","unstructured":"Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G (2003) Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316\u20132326","journal-title":"Clin Cancer Res"},{"key":"BF6604269_CR23","first-page":"479","volume":"10","author":"A Janus","year":"2005","unstructured":"Janus A, Robak T, Smolewski P (2005) The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10: 479\u2013948","journal-title":"Cell Mol Biol Lett"},{"key":"BF6604269_CR24","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/sj.bjc.6603656","volume":"96","author":"A Jimeno","year":"2007","unstructured":"Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, Chen R, Clark DP, Forastiere A, Hidalgo M (2007) Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96: 952\u2013959","journal-title":"Br J Cancer"},{"key":"BF6604269_CR25","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995\u20134004","journal-title":"Mol Cell Biol"},{"key":"BF6604269_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell 10: 151\u2013162","journal-title":"Mol Cell"},{"key":"BF6604269_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10555-007-9059-x","volume":"26","author":"G Melillo","year":"2007","unstructured":"Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26: 341\u2013352","journal-title":"Cancer Metastasis Rev"},{"key":"BF6604269_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","volume":"33","author":"J Mendelsohn","year":"2006","unstructured":"Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369\u2013385","journal-title":"Semin Oncol"},{"key":"BF6604269_CR29","doi-asserted-by":"crossref","unstructured":"Merchan JR (2007) Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. 2007 ASCO Annual Meeting Abstract - No. 5034","DOI":"10.1200\/jco.2007.25.18_suppl.5034"},{"key":"BF6604269_CR30","doi-asserted-by":"crossref","unstructured":"Patnaik A (2007) A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. 2007 ASCO Annual Meeting Abstract - No. 3512","DOI":"10.1200\/jco.2007.25.18_suppl.3512"},{"key":"BF6604269_CR31","doi-asserted-by":"publisher","first-page":"22473","DOI":"10.1074\/jbc.M500963200","volume":"280","author":"RJ Phillips","year":"2005","unstructured":"Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, Keane MP, Strieter RM (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase\/PTEN\/AKT\/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1\u03b1. J Biol Chem 280: 22473\u201322481","journal-title":"J Biol Chem"},{"key":"BF6604269_CR32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1593\/neo.05361","volume":"7","author":"RD Rao","year":"2005","unstructured":"Rao RD, Mladek AC, Lamont JD, Goble JM, Erlichman C, James CD, Sarkaria JN (2005) Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7: 921\u2013929","journal-title":"Neoplasia"},{"key":"BF6604269_CR33","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1200\/JCO.2005.04.2424","volume":"24","author":"F Rojo","year":"2006","unstructured":"Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J (2006) Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 24: 4309\u20134316","journal-title":"J Clin Oncol"},{"key":"BF6604269_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/01.cco.0000143964.74936.d1","volume":"16","author":"EK Rowinsky","year":"2004","unstructured":"Rowinsky EK (2004) Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16: 564\u2013575","journal-title":"Curr Opin Oncol"},{"key":"BF6604269_CR35","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","volume":"22","author":"A Sansal","year":"2004","unstructured":"Sansal A, Sellers WR (2004) The biology and clinical relevance of the PTEN tumor supressor pathway. J Clin Oncol 22: 2954\u20132963","journal-title":"J Clin Oncol"},{"key":"BF6604269_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","volume":"103","author":"T Schmelzle","year":"2000","unstructured":"Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253\u2013262","journal-title":"Cell"},{"key":"BF6604269_CR37","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1517\/13543784.15.10.1201","volume":"15","author":"P Smolewski","year":"2006","unstructured":"Smolewski P (2006) Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin Investig Drugs 15: 1201\u20131227","journal-title":"Expert Opin Investig Drugs"},{"key":"BF6604269_CR38","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-04-0808","volume":"10","author":"S Stephan","year":"2004","unstructured":"Stephan S, Datta K, Wang E, Li J, Brekken RA, Parangi S, Thorpe PE, Mukhopadhyay D (2004) Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 10: 6993\u20137000","journal-title":"Clin Cancer Res"},{"key":"BF6604269_CR39","doi-asserted-by":"crossref","unstructured":"van Oosterom AT, Reichardt P, Blay J, Dumez H, Fletcher J, Debiec-Rychter M, Shand N, Drimitrijevic S, Yap A, Demetri G (2004) Combination signal transduction inhibition: a phase I\/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). Abstract - No. 3002","DOI":"10.1200\/jco.2004.22.90140.3002"},{"key":"BF6604269_CR40","first-page":"5090","volume":"61","author":"A Viloria-Petit","year":"2001","unstructured":"Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS (2001) Acquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090\u20135101","journal-title":"Cancer Res"},{"key":"BF6604269_CR41","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489\u2013501","journal-title":"Nat Rev Cancer"},{"key":"BF6604269_CR42","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.1158\/0008-5472.CAN-04-4392","volume":"66","author":"MY Wang","year":"2006","unstructured":"Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66: 7864\u20137869","journal-title":"Cancer Res"},{"key":"BF6604269_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.0.CO;2-S","volume":"178","author":"Y Yu","year":"1999","unstructured":"Yu Y, Sato JD (1999) MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 178: 235\u2013246","journal-title":"J Cell Physiol"},{"key":"BF6604269_CR44","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/ncb999","volume":"5","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578\u2013581","journal-title":"Nat Cell Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604269","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:31:50Z","timestamp":1684413110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["BF6604269"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604269","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}